Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reissued by equities researchers at Wells Fargo & Co in a research report issued to clients and investors on Friday, AnalystRatings.com reports.
A number of other research analysts have also recently commented on CRSP. BidaskClub upgraded Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 30th. Goldman Sachs Group increased their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Chardan Capital reiterated a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Finally, Oppenheimer boosted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Two analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Crispr Therapeutics has an average rating of “Buy” and an average price target of $69.54.
Shares of CRSP stock opened at $72.37 on Friday. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market cap of $4.00 billion, a PE ratio of -21.04 and a beta of 3.30. The company’s fifty day simple moving average is $54.81 and its 200-day simple moving average is $47.38. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Equities research analysts expect that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last 90 days. Insiders own 21.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC purchased a new stake in Crispr Therapeutics during the 3rd quarter worth approximately $4,366,000. Orbimed Advisors LLC acquired a new position in shares of Crispr Therapeutics in the 3rd quarter valued at approximately $21,167,000. Granahan Investment Management Inc. MA boosted its stake in shares of Crispr Therapeutics by 8.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock valued at $1,418,000 after buying an additional 2,655 shares during the last quarter. Barclays PLC boosted its stake in shares of Crispr Therapeutics by 42.7% during the 3rd quarter. Barclays PLC now owns 13,877 shares of the company’s stock valued at $568,000 after buying an additional 4,151 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in shares of Crispr Therapeutics by 18.0% during the 3rd quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock valued at $400,000 after buying an additional 1,491 shares during the last quarter. Hedge funds and other institutional investors own 49.81% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Pattern Day Trader
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.